肺纤维化中的新兴疗法
Hugh Etchingham-Coll1, Ekrem Temizel2, Neso Okezie-Enyioma3
1School of Medicine, Ulster University, Londonderry, UK.
Pulmonary therapy
|February 24, 2026
概括
间歇性肺病 (ILD) 涉及肺炎和纤维化. 目前针对异常性肺纤维化 (IPF) 的治疗方法减缓了进展,但没有逆转损伤,推动了对新疗法的研究.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 纤维性疾病 纤维性疾病
背景情况:
- 间歇性肺部疾病 (ILDs) 涵盖了由炎症和纤维化标志的各种呼吸系统疾病.
- 异常性肺纤维化 (IPF) 是最常见和最严重的ILD,是一种慢性,渐进的疾病,导致不可逆转的肺功能下降.
- 目前的IPF治疗方法,包括皮尔费尼和宁泰达尼布,可以缓解肺功能下降,但不能恢复受损组织.
研究的目的:
- 审查ILDs的病原和流行情况.
- 探索IPF和渐进性肺纤维化目前的治疗策略.
- 讨论针对复杂的肺纤维化病理生理学的新兴疗法.
主要方法:
- 关于ILD病变发生,流行和治疗的文献综述.
- 对当前抗纤维菌疗法的分析 (皮尔费尼,宁泰达尼布,内兰多米拉斯).
- 对肺纤维化治疗的新型治疗方法的探索.
主要成果:
- ILD的特点是炎症和纤维化,IPF是主要的亚型.
- 现有的治疗方法,如皮尔费尼和宁泰达尼布,可以缓解症状,并减缓疾病的进展.
- 涅兰多米拉斯特是最近获得FDA批准的IPF和渐进性肺纤维化治疗方法.
结论:
- 尽管取得了进展,但IPF和其他ILD的当前治疗方法在逆转肺损伤方面存在局限性.
- 焦点正在转向开发具有增强有效性和安全性概况的新疗法.
- 未来的研究旨在准肺纤维化的复杂机制,以阻止或逆转疾病的进展.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
508
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
546
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
546
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
676
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
676
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
593
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
655
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
655
01:30Pulmonary Hypertension: Classification and Pathogenesis
706
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
706